Background
Hypomethylation in long interspersed nucleotide element-1 (LINE-1) and high-degree microsatellite instability (MSI-high) in colorectal cancer (CRC) have been associated with inferior and superior survival, respectively; however, it remains uncertain whether the prognostic association of LINE-1 hypomethylation differs by MSI status. We hypothesized that the adverse prognostic association of LINE-1 hypomethylation might be stronger in MSI-high CRCs than in microsatellite stable (MSS) CRCs.
Methods
Utilizing 1211 CRCs in the Nurses' Health Study and the Health Professionals Follow-up Study, we examined patient survival according to LINE-1 hypomethylation status in strata of MSI status. A Cox proportional hazards model was used to compute multivariable CRC-specific mortality hazard ratios (HRs) for a 10% decrease in LINE-1 methylation level (range = 23.1-93.1%), adjusting for potential confounders, including CpG island methylator phenotype, and KRAS, BRAF, and PIK3CA mutations. Statistical tests (log-rank test, chi-square test, and likelihood ratio test) were two-sided.
Results
In MSI-high cancers, the association of LINE-1 hypomethylation with higher mortality (HR = 2.45, 95% confidence interval [CI] = 1.64 to 3.66, P < .001) was stronger than that in MSS cancers (HR = 1.10, 95% CI = 0.98 to 1.24, P = .11) (P interaction < .001, between LINE-1 and MSI statuses). In MSI-high cases with CRC family history, the association of LINE-1 hypomethylation with higher mortality (HR = 5.13, 95% CI = 1.99 to 13.2; P < .001) was stronger than that in MSI-high cases without CRC family history (HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (P interaction = .02, between LINE-1 and CRC family history statuses).
Conclusions
The association of LINE-1 hypomethylation with inferior survival is stronger in MSI-high CRCs than in MSS CRCs. Tumor LINE-1 methylation level may be a useful prognostic biomarker to identify aggressive carcinomas among MSI-high CRCs.
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Colorectal cancer (CRC) represents a group of molecularly heterogeneous diseases characterized by differing sets of epigenetic and genetic abnormalities, including DNA hypomethylation in long interspersed nucleotide element-1 (LINE-1) and microsatellite instability (MSI) (1) (2) (3) (4) . LINE-1 constitutes a substantial portion (approximately 18%) of the human genome (5) , and methylation level in LINE-1 correlates with global DNA methylation status (6) . LINE-1 hypomethylated CRC has been associated with advanced stage or poor prognosis (7) (8) (9) (10) (11) (12) and inversely with MSI-high independent of the CpG island methylator phenotype (CIMP) (13, 14) .
High degree of MSI due to deficiency of DNA mismatch repair is observed in approximately 15% of CRCs and is a well established prognostic biomarker for better survival (15) (16) (17) (18) (19) (20) (21) .
However, a subset of patients of MSI-high CRCs still succumbs to the disease, and hence, additional biomarkers are needed to further classify MSI-high CRCs into different prognostic groups. Recent evidence suggests that LINE-1 hypomethylation is associated with higher mortality in MSI-high CRCs (9); however, it remains uncertain whether the prognostic association of LINE-1 hypomethylation differs by MSI status. We hypothesized that the adverse prognostic association of LINE-1 hypomethylation might be stronger in MSI-high CRCs (characterized by numerous somatic mutations [22] ) than in microsatellite stable (MSS) CRCs.
To test this hypothesis, we utilized a molecular pathological epidemiology database of 1211 CRCs in two prospective cohort studies and examined patient survival according to tumor LINE-1 methylation level (scale 0-100%) in strata of MSI status. Considering the potential influence of Lynch syndrome (23, 24) , we additionally examined the prognostic role of tumor LINE-1 methylation level within MSI-high CRC cases in strata of CRC family history status.
Methods

Study Cohorts
We utilized two US nationwide, prospective cohort studies: the Nurses' Health Study (NHS, involving 121 700 women who were enrolled in 1976) and the Health Professionals Follow-up Study (HPFS, involving 51 529 men who were enrolled in 1986) (25) . Every two years since these studies began, the participants have been sent follow-up questionnaires to update information on potential disease risk factors, and to identify newly diagnosed cancers and other diseases in themselves and their first-degree relatives. Lethal CRC cases were identified and confirmed by searching through the National Death Index. Study physicians reviewed all medical records related to CRC, extracted clinical information including stage and tumor location, and determined cause of death in deceased individuals. We collected paraffin-embedded tissue blocks from hospitals where participants with CRC had undergone tumor resection or diagnostic biopsy specimens.
Hematoxylin and eosin-stained tissue sections from all CRC cases were reviewed by a pathologist (S. Ogino) unaware of other data. Tumor differentiation was categorized as well to moderate vs poor (>50% vs ≤50% glandular area). We used available data on tumor LINE-1 methylation level, MSI status, and survival from 1211 CRC patients diagnosed up to 2008. Given the colorectal continuum model (26, 27) , we included both colon and rectal carcinomas in our primary analysis; we also examined colon cancer (excluding rectal cancer) in our secondary analysis. Patients were observed until death or January 1, 2012, whichever came first. The procedures and protocols of this study were approved by the institutional review boards for the Harvard School of Public Health and the Brigham and Women's Hospital. All subjects provided informed consent.
LINE-1 Methylation Analysis
DNA was extracted from archival tumor tissue. We performed bisulfite DNA treatment, polymerase chain reaction (PCR), and a pyrosequencing assay to quantify LINE-1 methylation level, after assay validation (28) . We primarily used LINE-1 methylation level as a continuous variable (scale 0-100%) in survival analyses. To display some of our results, we categorized the degree of LINE-1 hypomethylation status into three groups, namely "severe" (<55% methylation), "intermediate" (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) .9% methylation), and "mild/no" (≥65% methylation), consistent with our previous studies (29, 30) .
MSI Analysis
MSI analysis was performed utilizing a panel of 10 microsatellite markers, as previously described (20) . MSI-high was defined as instability in greater than or equal to 30% of the markers, and MSS status as instability in less than 30% of the markers (20) .
Analysis of CIMP, KRAS, BRAF, and PIK3CA Assessment of CIMP, KRAS, BRAF, and PIK3CA of CRCs in our cohorts (25, 31, 32) is described in the Supplementary Methods (available online).
Statistical Analysis
All statistical analyses were carried out using SAS (version 9.3, SAS Institute, Cary, NC). All P values were two-sided. Statistical significance level was set at P = .05 for testing of our primary hypothesis of an interaction between LINE-1 methylation level (continuous) and MSI status (binary) in CRC-specific survival analysis. A statistical interaction was assessed by likelihood ratio test, which compared the model with the interaction term (of LINE-1 and MSI statuses) to the model without the interaction term. For secondary and exploratory analyses, we recognized multiple comparisons inherent in subgroup analyses and interpreted our data very cautiously to avoid overinterpretation. For demographic categorical data, the chi-square test was performed. A t-test or analysis of variance (ANOVA), assuming equal variances, was used to compare mean age.
Kaplan-Meier method and log-rank test were used for survival analyses. For analyses of CRC-specific mortality, deaths as a result of other causes were censored. To control for confounding, we used multivariable Cox proportional hazards regression models. In addition to the LINE-1 hypomethylation variable (continuous; 10% decrease as a unit), the multivariable model initially included sex, age at diagnosis (continuous), year of diagnosis (continuous), family history of CRC in first-degree relative(s) (present vs absent), tumor location (proximal colon vs distal colon vs rectum), tumor differentiation (well to moderate vs poor), CIMP (high vs low/negative), and KRAS, BRAF, and PIK3CA mutations. A single analysis model could estimate the effect of LINE-1 hypomethylation in each stratum of MSI status, using a reparameterization of the interaction term (of LINE-1 and MSI statuses), as previously described (33) . To avoid overfitting, disease stage (I, II, III, IV, or unknown) (34) was used as a stratifying variable using the "strata" option in the SAS "proc phreg" command. A backward stepwise elimination was carried out with P = .05 as a threshold, to select variables for the final model. [7. 3%]), we included these cases in the majority category of a given covariate. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). The proportionality of hazards assumption was assessed by a time-varying covariate (an interaction term of survival time and LINE-1 hypomethylation variable, P > .15).
results
LINE-1 Hypomethylation and MSI Status in CRC
In 1211 incident CRCs within the two prospective cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study, we measured tumor LINE-1 methylation level (scale 0-100%), which ranged from 23.1% to 93.1% with mean of 62.7% and standard deviation of 9.4%. Normal colon mucosal tissue typically showed LINE-1 methylation level of 70% to 75% in our assay (14, 28) . There were 190 MSI-high CRCs and 1021 MSS CRCs. of LINE-1 hypomethylation was statistically significantly associated with higher disease stage (P = .001) and inversely associated with CIMP-high (P < .001) in MSS cases.
LINE-1 Hypomethylation, MSI Status, and CRC Mortality
Among 1211 patients, there were 648 deaths, including 356 CRC-specific deaths, during a median follow-up of 151 months (interquartile range: 110 to 204 months) for censored cases. We examined the relationship between LINE-1 hypomethylation and patient survival in all cases, and in strata of MSI status. In all CRC cases, tumor LINE-1 hypomethylation was associated with higher CRC-specific mortality in Kaplan-Meier analysis (log-rank P < .001) ( Figure 1 ) and in univariate and multivariable Cox regression analyses (for 10% decrease in LINE-1 methylation: multivariable hazard ratio [HR] = 1.16, 95% confidence interval (CI) = 1.03 to 1.30, P = .02) ( Table 2 ). For our main hypothesis testing, we examined statistical interaction between LINE-1 methylation level (continuous) and MSI status in CRC-specific survival analysis (Table 2) , which revealed a statistically significant interaction (P interaction < .001). In MSI-high CRCs, the association of LINE-1 hypomethylation with higher CRC-specific mortality was statistically significant (for 10% decrease in LINE-1 methylation: multivariable HR = 2.45, 95% CI = 1.64 to 3.66, P < .001) ( Table 2) . In MSS CRCs, the association of LINE-1 hypomethylation with CRC-specific mortality was weaker and not statistically significant (for 10% decrease in LINE-1 methylation: multivariable HR = 1.10, 95% CI = 0.98 to 1.24, P = .11) ( Table 2 ). Figure 1 shows Kaplan-Meier survival curves according to LINE-1 hypomethylation categories in MSI-high CRCs and in MSS CRCs. In secondary analyses of overall survival as an endpoint, there was a general trend toward differential prognostic associations of LINE-1 hypomethylation by MSI status, although the differences were not as evident as those in CRC-specific mortality analyses (Table 2 ; Supplementary Figure 1 , available online). Results of Kaplan-Meier analyses according to combined LINE-1 hypomethylation and MSI status are provided in Supplementary  Figure 2 (available online). Table 3 shows secondary analyses limited to colon cancer. The association of LINE-1 hypomethylation with higher colon cancerspecific mortality was stronger in MSI-high colon cancer than in MSS colon cancer (P interaction < .001, between LINE-1 and MSI statuses).
LINE-1 Hypomethylation, MSI/BRAF Status, and CRC Mortality
Although the utility of MSI/BRAF classification for prognostication in CRC has been demonstrated (20) , it is an imperfect marker; ie, some patients with favorable MSI-high/BRAF-wild-type tumors may die of cancer, while other patients with unfavorable MSS/BRAF-mutant tumors may survive. Hence, additional markers are needed to refine prognostic groups of CRC.
As a secondary analysis, we examined the relationship between LINE-1 hypomethylation and patient survival in strata of MSI/BRAF subtype ( Table 4 ). The association of LINE-1 hypomethylation with higher CRC-specific mortality appeared to be stronger in the MSI-high/BRAF-wild-type subtype (for 10% decrease in LINE-1 methylation; multivariable HR = 2.57, 95% 
LINE-1 Hypomethylation, CRC Family History, and Mortality in MSI-High CRC
The MSI-high/BRAF-wild-type subgroup of CRCs encompasses Lynch syndrome cases, which are familial cancers due to a germline mutation in one of mismatch repair genes. As an exploratory analysis, we focused on MSI-high cases and examined the relationship between tumor LINE-1 hypomethylation and patient survival in strata of CRC family history status ( Table 5 ). The association of LINE-1 hypomethylation with higher CRC-specific mortality appeared to be stronger in MSI-high cases with a family history of CRC in a first-degree relative (multivariable HR = 5.13, 95% CI = 1.99 to 13.2, P < .001) than in MSI-high cases without a family history of CRC in a first-degree relative (multivariable HR = 1.62, 95% CI = 0.89 to 2.94, P = .11) (P interaction = .02, between LINE-1 methylation and CRC family history status in MSI-high cases) (Table 5 ). Nonetheless, these results must be interpreted cautiously, given the exploratory nature of this subgroup analysis and the low event numbers.
LINE-1 Hypomethylation, MSI Status, Tumor Location, and CRC Mortality
Considering the interactive prognostic association between MSI status and tumor location reported by Sinicrope et al. (35), we examined the relationship between LINE-1 hypomethylation and patient survival in strata of MSI status and tumor location (Supplementary Table 1 , available online). The association of LINE-1 hypomethylation with mortality appeared to be modified by MSI status but not by tumor location, although statistical power was limited in this subgroup analysis.
Discussion
We conducted this study to test the hypothesis that the prognostic association of LINE-1 hypomethylation in CRC might be stronger in MSI-high CRCs than in MSS CRCs. Our data were consistent with this hypothesis, and the prognostic association of tumor LINE-1 hypomethylation indeed statistically significantly differed by MSI status. Although MSI-high is a well-established prognostic biomarker for better survival, a subset of MSI-high CRCs is lethal. In addition, our study has confirmed that tumor LINE-1 hypomethylation is associated with adverse prognosis in CRCs (7, 8) and in MSI-high CRCs (9) . Notably, our main hypothesis was that the prognostic association of tumor LINE-1 hypomethylation might be stronger in MSI-high CRCs (which are characterized by numerous somatic mutations [22] ) than in MSS CRCs. This unique hypothesis has never been tested in the previous studies. To test our main hypothesis, it was necessary to utilize a large number of CRCs with detailed molecular analyses, including statuses of both MSI and LINE-1 hypomethylation, as well as other molecular features such as KRAS, BRAF, and PIK3CA mutations to control for possible confounding.
Examining tumor molecular and host factors has become increasingly important in CRC (36-42). LINE-1 methylation level and MSI are both important molecular markers in CRC. LINE-1 methylation level is used as a surrogate marker for global DNA methylation (43) , and global DNA hypomethylation, indicated by LINE-1 hypomethylation, is associated with genomic and chromosomal instability (14, 44) . LINE-1 hypomethylation in CRC may also be a marker for familial susceptibility to CRC (30, 45) . MSI is a well-established biomarker that is routinely used for assessment of familial CRC (Lynch syndrome) risk in combination with BRAF testing (23) . LINE-1 hypomethylation is inversely associated with MSI-high, independent of CIMP (13, 14) , and LINE-1 hypomethylation (7-9), and MSI-high (15) (16) (17) (18) (19) (20) (21) are associated with inferior and superior prognosis, respectively.
To the best of our knowledge, this is among the first studies to address the interactive association between LINE-1 hypomethylation and MSI status in relation to the clinical outcome of CRC patients. Although some studies have shown the association of LINE-1 hypomethylation in CRCs with inferior survival, sample sizes of those studies would unlikely be adequate to analyze this interactive effect (sample size N = 643 [7] and N = 161 [8] ). Rhee et al. (9) showed that LINE-1 hypomethylation was associated with adverse prognosis in MSI-high CRCs, but they did not examine MSS CRCs. A recent study has shown that LINE-1 hypomethylation is an independent prognostic biomarker in early-stage rectal cancer, but they did not examine colon cancer (46) . Our resource of a large number of CRCs (N = 1211) has provided us with reasonable power to analyze this interactive association. Furthermore, we took into account other tumor molecular data, including CIMP, and KRAS, BRAF, and PIK3CA mutations.
Considering the utility of MSI/BRAF classification for prognostication in CRC (20) , as well as its routine clinical use for familial risk assessment (23), we additionally examined the prognostic association of LINE-1 hypomethylation in strata of MSI/BRAF subtype. The association of LINE-1 hypomethylation with inferior survival appeared to be stronger in the MSI-high/BRAF-wildtype subtype, which is known to imply the most favorable subtype among the four MSI/BRAF subtypes (20) . Although we should interpret the results cautiously, LINE-1 methylation level can potentially be used as an additional biomarker to refine the prognostic groups by MSI/BRAF classification.
Because the MSI-high/BRAF-wild-type CRC subgroup contains Lynch syndrome cases, we focused on MSI-high cases and examined the prognostic association of LINE-1 hypomethylation in strata of CRC family history status. The association of LINE-1 hypomethylation with inferior survival appeared to be stronger in MSI-high cases with a CRC family history than in MSI-high cases without a CRC family history. Nevertheless, we must interpret the results carefully to avoid overinterpretation, considering the exploratory nature of this analysis. Since the MSI-high/BRAFwild-type subtype and the MSI-high subtype with a CRC family history are enriched with Lynch syndrome cases (23), these intriguing results warrant further investigation to examine whether LINE-1 hypomethylation serves as an unfavorable prognostic biomarker in Lynch syndrome cases.
It is interesting, but challenging, to speculate potential mechanisms of interaction between LINE-1 methylation level and MSI status. Compared to MSS tumor, MSI-high CRC characterized by numerous somatic mutations (22) might be more influenced by genomic DNA or LINE-1 hypomethylation, which is associated with chromosomal instability (14, 44) . Other possible mechanisms may involve inflammatory mediators (47) (48) (49) (50) , variation in locusspecific methylation patterns (43,51-54), and non-coding RNAs KRAS, BRAF, and PIK3CA mutations. CI = confidence interval; CRC = colorectal cancer; HR = hazard ratio; LINE-1 = long interspersed nucleotide element-1; MSI = microsatellite instability. † P value was calculated using chi-square test (two-sided). ‡ P interaction value (between continuous LINE-1 methylation level and binary status of CRC family history) was calculated using likelihood ratio test (two-sided), which compared the model with the interaction term with the model without the interaction term.
(55-57). Further studies are required to elucidate the underlying mechanisms of the interactive prognostic association between tumor LINE-1 methylation level and MSI status. Some limitations of our study deserve discussion. Because data on cancer treatment were limited, unknown bias, including differential treatment assignment, might confound results. In survival analyses, we adjusted for disease stage, on which treatment decisions are mainly based. Another caveat relates to the study population. Health professionals may not be completely representative of the general US population. Nonetheless, the pathologic and molecular features of our CRC cases are generally compatible with data from the US cancer registry and published literature. Another limitation is that we excluded cases without available tumor data, which might cause bias. Nonetheless, a previous study has shown that there are no statistically significant demographic or clinical differences between cases with and without available tumor data (58) . Finally, we need to replicate the findings before implementing tumor LINE-1 methylation measurement as a clinical test following the guidelines (59) .
Strengths of this study include the use of data from the two US nationwide, prospective cohort studies. Information on cancer staging, family history of CRC, and other clinicopathologic and tumor molecular data was integrated into the molecular pathological epidemiology (60,61) database. Our cohort participants were treated at hospitals throughout the US and were more representative of CRC cases in the general US population than patients in only a few academic hospitals. Finally, by virtue of our database, we could assess the prognostic association of LINE-1 hypomethylation in strata of MSI status, while controlling for multiple potential confounders, including disease stage, CIMP, and KRAS, BRAF, and PIK3CA mutations.
In conclusion, we showed a stronger association of LINE-1 hypomethylation with inferior survival in MSI-high CRCs than in MSS CRCs, further attesting biological heterogeneity of MSI-high CRCs. LINE-1 methylation may be a useful prognostic biomarker to identify aggressive cancer cases among generally indolent MSIhigh CRCs. 
